Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Jan 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 22 Sep 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016 as reported in ClinicalTrials.gov record.
    • 22 Sep 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2016 as reported in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top